The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-…
The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants further shift the complicated treatment algorithm…
Market Outlook Treatment for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) has remained relatively unchanged in the past ten years, and Erbitux-based regimens…
DRG Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in 12 major mature pharmaceutical markets (Austria, Belgium, Czech…
DRG Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in seven emerging pharmaceutical markets (Brazil, Russia, India, China,…
DRG Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in the Americas (Argentina, Canada, Chile, Colombia, and Peru). We report…
DRG Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in the Asia-Pacific (Hong Kong, Philippines, Taiwan, Thailand, Vietnam,…
DRG Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in seven major mature pharmaceutical markets (the United States, France…
DRG Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in the Middle East and Africa (Egypt, Nigeria, Saudi Arabia, and South…
DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key schizophrenia patient populations covering 171 countries and more than 99…
The 2016/17 FDA approvals of five immune checkpoint inhibitors for platinum-treated patients have significantly altered the treatment landscape for advanced bladder cancer, which has historically…
PsA, a disease characterized by flaky psoriatic skin lesions, erosive joint damage, and complicating comorbidities, remains poorly understood, underdiagnosed, and undertreated. Nevertheless, TNF…
DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key peripheral arterial disease patient populations covering 171 countries…
Pancreatic cancer is a notoriously aggressive and hard-to-treat malignancy; the five-year survival rate is around 10%. Treatment options for pancreatic cancer are limited to surgery, radiation, and…
The type 2 diabetes (T2D) therapy market is expected to expand, fueled by a rich pipeline of agents. However, growth will be tempered because these emerging therapies will be predominantly later-to…